Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2), commonly known as GLUT2, is a low-affinity, high-capacity transmembrane glycoprotein that mediates the bidirectional facilitated transport of glucose, fructose, and galactose across cell membranes. It is primarily expressed in key metabolic tissues, including hepatocytes, pancreatic beta cells, renal proximal tubules, and the basolateral membrane of intestinal epithelial cells, where it plays a pivotal role in maintaining systemic glucose homeostasis and acting as a glucose sensor. In pancreatic beta cells, GLUT2-mediated glucose uptake couples extracellular glucose levels to insulin secretion, while in hepatocytes, it regulates glucose uptake during feeding and glucose release during fasting.\n\nDysregulation or genetic mutations in SLC2A2 are strongly associated with metabolic disorders and malignancies. Biallelic loss-of-function mutations in SLC2A2 cause Fanconi-Bickel syndrome, a rare glycogen storage disease characterized by hepatorenal glycogen accumulation, renal tubular dysfunction, and severe dysglycemia. Furthermore, common polymorphisms in SLC2A2 are linked to type 2 diabetes susceptibility and can modulate patient responsiveness to antidiabetic therapies like metformin. In oncology, altered SLC2A2 expression is observed in cancers such as hepatocellular carcinoma and gastric cancer, where it supports the high metabolic demands of tumor cells, making it an attractive target for diagnostic, prognostic, and therapeutic interventions.
Drugs targeting SLC2A2 (GLUT2) act primarily by inhibiting its facilitative hexose transport activity, thereby blocking the cellular uptake of glucose or fructose. Some natural compounds and small molecules act as competitive or non-competitive inhibitors of GLUT2 to manage hyperglycemia or reduce cancer cell proliferation. Conversely, certain cytotoxic agents like streptozocin utilize GLUT2 as a portal for cellular entry to selectively destroy pancreatic beta cells. Additionally, some drugs indirectly modulate GLUT2 expression levels to restore glucose homeostasis.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 2 (GLUT2) (SLC2A2).